Cipla inks pact with US firm for Ropivacaine infusion system

Published On 2016-01-07 05:31 GMT   |   Update On 2016-01-07 05:31 GMT
Advertisement
New Delhi: Drug major Cipla has inked a pact with US-based BioQ Pharma for registration and commercialisation of latter's Ropivacaine infusion system, used in treating post-operative pain, in India.

BioQ Pharma and Cipla have inked a strategic distribution, supply and development agreement for the registration and commercialisation of BioQ Pharma's Ropivacaine infusion pharmaceutical in India, the companies said in a joint statement.

"We believe this innovative product represents a significant evolution in enhancing the delivery of infusions and managing post-surgical pain," Cipla's India Business Head, Nikhil Chopra said.

BioQ Pharma's unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care.

In particular, the Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution.

BioQ Pharma, President and CEO, Josh Kriesel said the company is excited to collaborate with Cipla and expand its worldwide commercial footprint into India.

"We believe India is an excellent market to help expand our objective of establishing a new standard of care in the presentation and administration of infusible pharmaceuticals," he added.

Cipla's proven, hospital-focused sales and marketing organisation will be essential in introducing BioQ Pharma's proprietary unit-dose, large volume infusion pharmaceuticals to India's healthcare market, Kriesel said.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News